US SEC Trading Suspension Halt Orders — March 20, 2026

20-03-2026

On March 18, 2026, GoHealth, Inc. received a Nasdaq notice for non-compliance with Listing Rule 5550(b)(2), as its market value of listed securities falls below the $35M threshold and it fails alternative standards of $2.5M stockholders’ equity or $500K net income. Trading of Class A Common Stock (GOCO) continues uninterrupted on The Nasdaq Global Market, with a 180-day compliance period until September 14, 2026, to achieve $35M MVLS for at least 10 consecutive business days. The company is evaluating options but provides no assurance of regaining compliance, risking delisting and potential appeal.

• ·Compliance requires MVLS closing at $35M or more for minimum 10 consecutive business days (Nasdaq may extend to 20)
• ·Non-compliance after September 14, 2026, triggers delisting notice with option to appeal to Nasdaq Hearings Panel, staying suspension

20-03-2026

Alzamend Neuro, Inc. received a Nasdaq notice on March 20, 2026, indicating that its stockholders' equity of $2.2M as of January 31, 2026, failed to meet the $2.5M minimum requirement under Listing Rule 5550(b)(1). While trading of ALZN common stock continues uninterrupted on Nasdaq Capital Market, the company has 45 days until May 4, 2026, to submit a compliance plan, with potential extension to September 16, 2026, if accepted. There is no assurance of compliance or avoidance of delisting.

• ·Nasdaq provides initial 45 calendar days from March 20, 2026, to submit compliance plan.
• ·If plan accepted, up to 180 calendar days from letter date to evidence compliance.

20-03-2026

On March 17, 2026, Lifeward Ltd. received a Nasdaq notice of non-compliance with Listing Rule 5605(c)(2)(A) after Hadar Levy's resignation from the Board reduced the Audit Committee to two members, below the required three. The company has a cure period until the earlier of its next annual shareholders' meeting or February 24, 2027 (or August 24, 2026, if the meeting is before then) to regain compliance, with no assurance of success. Shares continue trading on Nasdaq Capital Market under LFWD without immediate delisting impact.

• ·Nasdaq Listing Rule 5605(c)(2)(A) requires audit committee of at least three members.
• ·Company reviewing options to regain compliance per Nasdaq Rule 5605(c)(4).

20-03-2026

Quince Therapeutics, Inc. received Nasdaq notices on March 16 and 17, 2026, stating that its common stock failed the Minimum Bid Price Requirement (closing below $1.00 per share for 30 consecutive business days) and the Market Value of Listed Securities (MVLS) Requirement (below $50M for 30 consecutive business days). The company has 180 calendar days until September 14, 2026, to regain compliance by meeting each threshold for at least 10 consecutive business days (potentially up to 20). Non-compliance risks delisting or transfer to Nasdaq Capital Market, though trading continues uninterrupted on Nasdaq Global Select Market under QNCX.

• ·Company may transfer to Nasdaq Capital Market for additional compliance time if meeting other standards except bid price, via reverse stock split if necessary.
• ·Nasdaq may appeal delisting to Listing Qualifications Panel, but no assurance of approval.
• ·Common stock: par value $0.001 per share, trading symbol QNCX.

20-03-2026

On March 16, 2026, MaxCyte, Inc. received a notice from Nasdaq indicating that its common stock (MXCT) failed to satisfy the minimum bid price requirement of $1.00 per share for 30 consecutive trading days, violating Nasdaq Listing Rule 5450(a)(1). The company has an initial 180-day compliance period until September 14, 2026, to regain compliance by achieving $1.00+ closing prices for 10 consecutive trading days, with no immediate impact on current listing or trading on the Nasdaq Global Select Market. Failure to comply could lead to delisting or a potential transfer to the Nasdaq Capital Market with an additional 180-day period, subject to Nasdaq's determination of curability.

• ·MaxCyte, Inc. is an emerging growth company.
• ·Trading symbol: MXCT.
• ·Company provided with compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

20-03-2026

Ernexa Therapeutics Inc. received a Nasdaq notice on March 18, 2026, indicating its common stock (ERNA) failed to maintain a $1.00 minimum bid price for 30 consecutive business days, violating Listing Rule 5550(a)(2). Due to a reverse stock split within the prior year, the company is ineligible for the standard 180-day compliance period and intends to request a hearing before the Nasdaq Hearing Panel for a potential extension of up to 180 days. There are no assurances of a favorable outcome, which could lead to delisting of ERNA and ERNAW.

• ·Company ineligible for 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to reverse stock split in prior one-year period.
• ·Hearing request will stay delisting pending Panel decision and any extension.
• ·Principal executive offices: 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141; Phone: (617) 798-6700.

20-03-2026

On March 16, 2026, NextNRG, Inc. received a notice from Nasdaq's Listing Qualifications Department for failing to meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) over the last 30 consecutive business days, with no immediate impact on trading of its common stock (NXXT). The company has 180 calendar days until September 14, 2026, to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days, or potentially receive an additional 180 days via reverse stock split if other listing criteria are met. There is no assurance of regaining compliance, and the company is evaluating options but has made no decisions.

• ·Trading symbol: NXXT
• ·Commission File Number: 001-40809
• ·IRS Employer Identification No.: 84-4260623
• ·Principal executive offices: 407 Lincoln Rd. #9F, Miami Beach, Florida 33190
• ·Registrant is an emerging growth company

20-03-2026

IP Strategy Holdings, Inc. (IPST) received a Nasdaq notice on March 20, 2026, stating that its common stock failed the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2), with the closing bid price below $1.00 for 30 consecutive business days. The company is ineligible for the standard 180-calendar-day compliance period due to a prior 1-for-20 reverse stock split on November 5, 2025, prompting plans to appeal by March 27, 2026, and a special stockholder meeting on April 10, 2026, to approve another reverse stock split (1:3 to 1:20). No assurance exists that these actions will enable regaining compliance before the Nasdaq hearing.

• ·Record date for special stockholder meeting: March 19, 2026
• ·Appeal filing deadline: no later than March 27, 2026
• ·Nasdaq Listing Rule cited: 5550(a)(2) and 5810(c)(3)(A)(iv)

20-03-2026

Tivic Health Systems, Inc. (TIVC) received a Nasdaq notification on March 19, 2026, for non-compliance with the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)), as its common stock closing bid price was below $1.00 for 30 consecutive business days. The listing remains effective with no immediate impact, providing 180 calendar days until September 15, 2026, to regain compliance by closing at or above $1.00 for 10 consecutive business days; failure could lead to delisting, though a second 180-day period or appeal may be possible. The Company intends to monitor the stock price and explore options to cure the deficiency, with no assurance of success.

• ·Nasdaq Listing Rule 5810(c)(3)(A) governs the compliance period
• ·Second grace period requires meeting other Nasdaq Capital Market listing standards except minimum bid price
• ·Company classified as emerging growth company
• ·Right to appeal delisting determination to Nasdaq Hearings Panel

20-03-2026

Faraday Future Intelligent Electric Inc. received a Nasdaq notice on March 20, 2026, for failing to maintain a minimum $1.00 bid price for its Class A common stock (FFAI) over 30 consecutive trading days from February 5 to March 19, 2026, violating Listing Rule 5550(a)(2). The company has 180 calendar days until September 16, 2026, to regain compliance by sustaining a $1.00 closing bid price for at least 10 consecutive trading days, or risk delisting, though a second compliance period or reverse stock split could be options. Continued trading on Nasdaq Capital Market is allowed during this period, but a bid price of $0.10 or less for 10 consecutive days would trigger immediate delisting proceedings.

• ·Compliance period allows up to 20 business days at Nasdaq's discretion instead of 10 for bid price regainment.
• ·Second 180-day period possible if company meets market value of publicly held shares and other Nasdaq Capital Market initial listing standards (except bid price).

20-03-2026

TELA Bio, Inc. received a Nasdaq deficiency notice on March 17, 2026, stating that its common stock (TELA) closing bid price was below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has 180 calendar days until September 14, 2026, to regain compliance by closing at $1.00 or higher for 10 consecutive business days, with trading continuing uninterrupted for now and a possible second 180-day period if transferred to Nasdaq Capital Market. The company intends to monitor and address the issue, but success is not assured.

• ·Nasdaq deficiency letter issued by Listing Qualifications Department Staff.
• ·Company headquartered at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
• ·Trading symbol: TELA.